Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea-Reference-Cited by-同舟云学术

Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea

Published:2012-01 Issue:1 Volume:159 Page:25-31
ISSN:1931-5244
Container-title:Translational Research
language:en
Short-container-title:Translational Research

Author:

Aso Yoshimasa,Ozeki Noriyuki,Terasawa Tomoko,Naruse Rika,Hara Kenji,Suetsugu Mariko,Takebayashi Kohzo,Shibazaki Mitsuei,Haruki Kohsuke,Morita Kimio,Inukai Toshihiko

Publisher

Elsevier BV

Subject

Biochemistry (medical),Public Health, Environmental and Occupational Health,General Medicine,Physiology (medical)

Reference29 articles.

1. The role of incretins in glucose homeostasis and diabetes treatment;Kim;Pharmacol Rev,2008

2. The physiology of glucagon-like peptide 1;Holst;Physiol Rev,2007

3. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes;Nauck;Diabetologia,1986

4. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use;Kendall;Am J Med,2009

5. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme;Matteucci;Curr Med Chem,2009

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring serum Dipeptidyl peptidase-4 levels: Associations with diabetes, glucose control and peripheral artery disease;South Asian Journal of Health Sciences;2024-05-27

2. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid diagnosed by oral manifestation;Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology;2023-11

3. Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub‐analysis of the DIVERSITY‐CVR study;Diabetes, Obesity and Metabolism;2023-05-08

4. Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice;Endokrynologia Polska;2023-04-28

5. Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes;Diabetes Research and Clinical Practice;2022-10